Talha Badar

Dec 31, 2024 | mdpi.com | Talha Badar

Article Menu /ajax/scifeed/subscribe Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.

Feb 12, 2024 | onlinelibrary.wiley.com | Yasmin Abaza |Eric S. Winer |Rory M. Shallis |Andrew Matthews |Talha Badar |Emily M. Geramita | +6 more

1 INTRODUCTION Acute myeloid leukemia (AML) is primarily a disease of the elderly with a median age at diagnosis of 69 years.1 Treatment of patients with AML ≥75 years of age, who are truly unfit for intensive chemotherapy, is challenging given the higher incidence of adverse risk disease, comorbidities, poor performance status, and compromised organ function.2-4 Although the outcomes of AML have significantly improved over the past 5 decades, the long-term survival remains poor with the...

Feb 7, 2024 | onclive.com | Talha Badar

Talha Badar, MBBS, MD, hematologist/oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic, discusses key efficacy findings derived from treatment with imetelstat from the phase 2/3 IMerge trial (NCT02598661) of patients with lower-risk myelodysplastic syndrome (MDS).

Sep 26, 2023 | futuremedicine.com | Talha Badar |Yazan Madanat |Amer M Zeidan

T Badar served on an advisory board for Pfizer and Takeda. T Badar received travel reimbursement from DAVA Oncology and Cardinal Health. YF Madanat has received honoraria/consulting fees from Blueprint Medicines, GERON, OncLive and MD Education. YF Madanat participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphoses, Taiho Oncology, Rigel Pharmaceuticals and Novartis.